Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First Results of Concurrent Chemoradiation with Two Courses of 5 × 25 mg/m<sup>2</sup> Cisplatin for Locally Advanced Head and Neck Cancer.

Journal of personalized medicine·2023
Same author

Hypo-fractionated Radiotherapy (HF-RT) <i>Versus</i> Conventionally Fractionated Radiotherapy (CF-RT) for Glioblastoma.

Anticancer research·2023
Same author

Whole-brain Radiotherapy With or Without a Simultaneous Integrated Boost for Treatment of Brain Metastases.

Anticancer research·2023
Same author

Radiosurgery for ventricular tachycardia (RAVENTA): interim analysis of a multicenter multiplatform feasibility trial.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2023
Same author

Prognostic impact of the loss of E-cadherin and <i>de novo</i> expression of N-cadherin at the invasive front of primary and recurrent oral squamous cell carcinoma.

Frontiers in oncology·2023
Same author

Differential Effects of Anti-PD-1/PD-L1 Checkpoint Inhibitors on Adhesion Molecules and Cytokine Secretion by THP-1 Monocytes.

Anticancer research·2023

Related Experiment Video

Updated: Jul 15, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K

Simultaneous vs. Sequential Boost for Adjuvant Breast Radiotherapy.

Marie C Eggert1, Stefan Janssen1, Nathan Y Yu2

  • 1Department of Radiation Oncology, University of Lübeck, Lübeck, Germany.

Anticancer Research
|September 29, 2023
PubMed
Summary
This summary is machine-generated.

Conventional fractionation with simultaneous integrated boosts (CF+SIB) for breast cancer shows similar long-term outcomes and toxicity compared to sequential boosts (CF+SEB), but reduces treatment time by one week.

Keywords:
Breast canceradjuvant irradiationsequential boostsimultaneous integrated boosttoxicitiestreatment outcomes

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.4K
Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.2K

Related Experiment Videos

Last Updated: Jul 15, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.4K
Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.2K

Area of Science:

  • Oncology
  • Radiation Oncology
  • Clinical Trials

Background:

  • Adjuvant radiotherapy (RT) for breast cancer has seen a rise in alternative regimens.
  • Simultaneous integrated boosts (SIB) are increasingly favored over sequential boosts (SEB).

Purpose of the Study:

  • To compare long-term outcomes of conventional fractionation (CF) plus SIB versus CF plus SEB in breast cancer patients.
  • To evaluate toxicity profiles and survival rates between the two adjuvant radiotherapy approaches.

Main Methods:

  • A matched-cohort study comparing 48 patients receiving CF+SIB (5.5 weeks) to 72 patients receiving CF+SEB (6.5 weeks).
  • Patients were matched on twelve characteristics.
  • Outcomes assessed included radiation dermatitis, pneumonitis, local control (LC), metastases-free survival (MFS), cancer-specific survival (CSS), and overall survival (OS).

Main Results:

  • Rates of grade ≥2 dermatitis were 35.4% (CF+SIB) vs. 45.8% (CF+SEB) (p=0.26).
  • Rates of grade ≥2 pneumonitis were 0% (CF+SIB) vs. 4.2% (CF+SEB) (p=0.27).
  • Six-year survival rates (LC, MFS, CSS, OS) were comparable between CF+SIB and CF+SEB groups, with no statistically significant differences.

Conclusions:

  • Conventional fractionation with simultaneous integrated boosts (CF+SIB) is a viable alternative to sequential boosts (CF+SEB) for adjuvant breast cancer radiotherapy.
  • CF+SIB demonstrates comparable efficacy and toxicity to CF+SEB.
  • CF+SIB significantly reduces the overall treatment duration by one week.